Latest Headlines
CATEGORY
-
2023-04-19Biosyngen announces FDA IND approval of its second product for EBV-positive lymphomaApril 15, 2023, Biosyngen Pte Ltd (hereinafter as “Biosyngen”) announced that the Company received IND approval for its second product in the pipeline, a T-cell redirection therapy for the treatment of EBV-positive lymphoma. A week prior to this, the IND application of the same therapy has just beenREAD MORE -
2023-04-11Biosyngen received China NMPA IND approval for its T-cell redirection therapy targeting EBV-positive LymphomaApril 7th, 2023, Biosyngen Pte Ltd (hereinafter as “Biosyngen”) was granted IND approval by China NMPA for the company’s first-in-class T-cell redirection therapy, it is an autologous T cell therapy for EBV-positive lymphoma. The principle of autologous T cell therapy is to genetically modify patienREAD MORE -
2023-03-29PM Lee receives a first-hand update by Biosyngen on its progress in cell therapyThe city of Guangzhou welcomes Singapore Prime Minister Lee Hsien Loong, the first stop of his week-long visit to China. Accompanying PM Lee in this trip are Foreign Minister Vivian Balakrishnan, Trade and Industry Minister Gan Kim Yong, Health Minister Ong Ye Kung, Senior Minister of State for ForeREAD MORE -
2023-02-17Biosyngen has obtained FDA IND clearance of BRG01 for Phase I/II clinical trials against Nasopharyngeal CancerFebruary 16th, 2023, Biosyngen Pte Ltd (hereinafter as "Biosyngen") was granted approval by US FDA for the company's IND application for BRG01 cell therapy, path the way for Phase I/II clinical trial. BRG01 is an autologous T cell therapy for relapsed/metastatic nasopharyngeal cancer (NPC) treatmentREAD MORE -
2022-12-14IND Application of Biosyngen’s Cell Therapy (BRG01) for Nasopharyngeal Cancer Approved by China NMPAOn Dec. 14th, 2022, Guangzhou Biosyngen Co., Ltd. (hereinafter as “Biosyngen”) made an announcement on the approval granted by the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) for the company’s IND application for BRG01 Therapy. BRG01 Therapy is an autoREAD MORE -
2022-11-16Biosyngen featured in the “Top 50 Most Innovative Companies of Chinese Biomedicine in 2022”, Pharma BigstarOn November 10th to 11th, 2022, the Shanghai (Minhang) Biopharmaceutical Industry Innovation Summit and the Universal Cell Therapy Development Forum 2022 were successfully held in Shanghai. The "Top 50 Most Innovative Biopharmaceutical Companies in China 2022" was unveiled during the forum.READ MORE
